DashboardAll companies
Run this on your own research
Healthcare · Diagnostics & Research

Guardant Health Inc.

GHNASDAQ$169.08+$6.14 (+3.77%)Market closed

Price Chart

Daily

Key facts

Market Cap
$22.47B
P/E
−50.9x
P/B
−213.46x
ROE
348.4%

Guardant Health Inc.

Healthcare · Diagnostics & Research · FY 2025

Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.

CEO
Dr. Helmy Eltoukhy Ph.D.
Employees
1,999

Company Statistics

Valuation

P/E
−50.9x
P/B
−213.46x
P/S
21.59x
EV/EBITDA
−60.3x
P/FCF
−91.0x

Margins

Gross
64.5%
EBITDA
−38.1%
Operating
−44.5%
Pre-Tax
−42.5%
Net
−42.4%

Returns

ROA
−23.8%
ROE
348.4%
ROIC
−23.6%

Growth (CAGR)

Rev 3Yr
29.8%
Rev 5Yr
27.9%
Op Inc 3Yr
—
Net Inc 3Yr
—

Financial Health

Cash & Cash Equivalents
$378.2M
Net Debt
$1.73B
Debt/Equity
−2127.7%
Interest Cov
—

Profile

Revenue
$982.0M
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Guardant Health Inc. (GH) Stock Forecast 2026 $169.08 — Price, Financials & Analyst Targets | AlphaLenz